← QL Research Library
WATCHOPENEVIDENCELOW conviction · open✦ Commissioned

OpenEvidence (Private): Adoption Is Real; the $15B Mark Is Still an Assert — WATCH

Published · entry price $ · machine-generated by the QuantLogix Thesis Engine and graded publicly at T+7/30/90 days · OPENEVIDENCE charts & signals →

OpenEvidence has arguably the strongest physician adoption of any clinical AI assistant in the US, built on a citation-first architecture that materially reduces hallucination liability. But the reported $500M-to-$15B valuation narrative is driven by asset scarcity in AI healthcare, not by disclosed revenue, and the reported $250M round still leading the funding tape suggests the mark is a choice, not a constraint. We stay WATCH: the weighted scenario fair value of ~$12.55B sits ~16% below the reported ask, and the falsifiable trigger is the next priced round's mark.

★ Follow this thesis Get notified as the position plays out — claim triggers, T+7/30/90 grades, and invalidation, by push and in-app. Pro members can also opt into email updates.

Thesis

Evidence Graph4 of 4 claims linked · 5 preserved sources
Claim coverage4 / 4claims with evidence
Directional edges43 support · 1 challenge
Freshness4 / 5Latest dated source 11/16/2026
ConvictionLOW0 recorded changes

This graph uses only evidence frozen into the thesis at publication on 11/21/2026. “Retrieved source passage” is the preserved grounding excerpt the engine saw; “published note passage” is thesis context, not a source quote. Missing edges and dates remain visible.

C1Invalidation rule
1 linked source

OpenEvidence's next priced financing round or confirmed sale marks the company at or above $10B, validating the adoption-to-monetization handoff the current markup anticipates.

G3SupportsExternal sourceOpen source
Inside OpenEvidence: The Art of Selling a $500M Company for $15B
Published · fixhealth.ai

The Fix Health report describes a $500M-to-$15B valuation narrative circulating among people familiar with the company, implying the next priced event is the test of that mark.

Retrieved source passage
Inside OpenEvidence: The Art of Selling a $500M Company for $15B Inside OpenEvidence: The Art of Selling a $500M Company for $15B People familiar with the company describe how CEO Daniel Nadler runs the company more like a hedge fund than a healthcare AI business. Oct 15, 2026 ∙ Paid Photo of OpenEvidence CEO Daniel Nadler taken from a video of his July 15, 2026, interview at Goldman Sachs. Additional visual elements, including a money bag and a stethoscope, were added using Google Gemini. Disclosure: I am an independent journalist. I have no financial position in OpenEvidence, Doximity, Teladoc, Waystar, Clarivate, Alphabet (Google), RELX (Elsevier), Wolters Kluwer, Wiley, Epic, Abrid
C2
2 linked sources

OpenEvidence is the most widely used physician-facing AI assistant in the United States, giving it category-leading distribution.

G1SupportsExternal sourceOpen source
Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short
Published · businesswire.com

BusinessWire's November 2026 release independently characterizes OpenEvidence as 'the most popular AI for doctors in the United States' in Every Cure's partnership announcement.

Retrieved source passage
Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short Every Cure and OpenEvidence partner to repurpose drugs where commercial incentives fall short. MIAMI & PHILADELPHIA--(BUSINESS WIRE)-- Every Cure, a nonprofit biotech organization dedicated to saving and improving lives through drug repurposing, today announced a partnership with OpenEvidence, the most popular AI for doctors in the United States, to turn existing medicines into new treatments for patients who have run out of options. By connecting Every Cure’s AI-driven engine with OpenEvidence’s proprietar
G2Context matchExternal sourceOpen source
Report: OpenEvidence Business Breakdown & Founding Story
Publication date not preserved · research.contrary.com

Contrary Research documents the product surface — 35 million peer-reviewed publications, mandatory citations — that would support broad physician adoption, but provides no user counts.

Retrieved source passage
Report: OpenEvidence Business Breakdown & Founding Story Contrary Research OpenEvidence OpenEvidence addresses information overload and physician shortages by providing a medical chat interface that draws answers from 35 million peer-reviewed medical publications, as of February 2025. Each OpenEvidence answer includes direct citations to the underlying research, allowing physicians to verify recommendations while accessing evidence-based answers for complex clinical questions. If medical research is inconclusive regarding a question, the platform will not provide a response, therefore reducing the chances of hallucinations. Founded 2021 HQ Cambridge, MA Funding $317M Stage Series B Emplo
C3
2 linked sources

OpenEvidence's citation-first design materially reduces hallucination and liability risk relative to general-purpose LLM competitors in clinical settings.

G2SupportsExternal sourceOpen source
Report: OpenEvidence Business Breakdown & Founding Story
Publication date not preserved · research.contrary.com

Contrary Research notes the platform refuses to answer when evidence is inconclusive, directly reducing hallucination frequency by construction.

Retrieved source passage
Report: OpenEvidence Business Breakdown & Founding Story Contrary Research OpenEvidence OpenEvidence addresses information overload and physician shortages by providing a medical chat interface that draws answers from 35 million peer-reviewed medical publications, as of February 2025. Each OpenEvidence answer includes direct citations to the underlying research, allowing physicians to verify recommendations while accessing evidence-based answers for complex clinical questions. If medical research is inconclusive regarding a question, the platform will not provide a response, therefore reducing the chances of hallucinations. Founded 2021 HQ Cambridge, MA Funding $317M Stage Series B Emplo
G4Context matchExternal sourceOpen source
Medical students should ‘learn the hard way,’ AI startup CEO says Semafor
Published · semafor.com

Nadler's own warning about 'cognitive offloading' shows management is aware of misuse-risk optics, which bears on regulatory and reputational exposure rather than resolving architecture quality.

Retrieved source passage
Medical students should ‘learn the hard way,’ AI startup CEO says Semafor Medical students should ‘learn the hard way,’ AI startup CEO says Nov 16, 2026, 8:48pm EST Nov 16, 2026, 8:48pm EST Kris Tripplaar/Semafor The CEO of a major medical AI startup said on Monday that medical students should do paper exams and master the material, even if they also use AI. “The risk of cognitive offloading is really, really acute,” OpenEvidence CEO Daniel Nadler said at Semafor’s Silicon Valley & The World. He would advise students to “train classically, learn classically, learn the hard way, do paper exams, do paper tests, make sure you actually know it,” he told Semafor’s Mohammed Sergie. Nadler’s co
C4
2 linked sources

The gap between reported adoption and disclosed revenue widens into 2027, meaning the valuation markup is driven more by scarcity of clinical-AI assets than by monetization evidence.

G3ChallengesExternal sourceOpen source
Inside OpenEvidence: The Art of Selling a $500M Company for $15B
Published · fixhealth.ai

The piece characterizes the company as run 'more like a hedge fund than a healthcare AI business' and frames the outcome as selling a $500M company for $15B — valuation craft over disclosed economics.

Retrieved source passage
Inside OpenEvidence: The Art of Selling a $500M Company for $15B Inside OpenEvidence: The Art of Selling a $500M Company for $15B People familiar with the company describe how CEO Daniel Nadler runs the company more like a hedge fund than a healthcare AI business. Oct 15, 2026 ∙ Paid Photo of OpenEvidence CEO Daniel Nadler taken from a video of his July 15, 2026, interview at Goldman Sachs. Additional visual elements, including a money bag and a stethoscope, were added using Google Gemini. Disclosure: I am an independent journalist. I have no financial position in OpenEvidence, Doximity, Teladoc, Waystar, Clarivate, Alphabet (Google), RELX (Elsevier), Wolters Kluwer, Wiley, Epic, Abrid
G1Context matchExternal sourceOpen source
Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short
Published · businesswire.com

The flagship November partnership is with a nonprofit (Every Cure) in drug repurposing — distribution-building but revenue-light, consistent with scale-first monetization.

Retrieved source passage
Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short Every Cure and OpenEvidence Partner to Repurpose Drugs Where Commercial Incentives Fall Short Every Cure and OpenEvidence partner to repurpose drugs where commercial incentives fall short. MIAMI & PHILADELPHIA--(BUSINESS WIRE)-- Every Cure, a nonprofit biotech organization dedicated to saving and improving lives through drug repurposing, today announced a partnership with OpenEvidence, the most popular AI for doctors in the United States, to turn existing medicines into new treatments for patients who have run out of options. By connecting Every Cure’s AI-driven engine with OpenEvidence’s proprietar

Unmapped source register

1 source

These links were preserved in the note but cannot be honestly assigned to a specific claim.

S5UnmappedQuantLogix coverageOpen source
quantlogix.ai
Published · quantlogix.ai
Published note passage
I assistant (founded 2021, Cambridge, MA; $317M raised per [Contrary Research]), with a reported $250M round leading our funding tape on both 09/27/2026 and 09/28/2026 ([QL briefing 9/28]).

What changed

Complete, timestamped thesis history.

  1. Thesis published
    WATCH · LOW conviction

OpenEvidence (Private): Adoption Is Real; the $15B Mark Is Still an Assert — WATCH

Setup

OpenEvidence is a private, Series B-stage clinical AI assistant (founded 2021, Cambridge, MA; $317M raised per Contrary Research), with a reported $250M round leading our funding tape on both 09/27/2026 and 09/28/2026 (QL briefing 9/28). This name sits in no qualifying T+30 cohort, so any directional verdict publishes as WATCH — and the honest answer is that WATCH is also what the evidence supports. Our pre-policy directional record is -2.06% across 41 calls, which is exactly why we refuse to dress a valuation opinion as a graded call when the decisive data point (the next priced round) has not printed.

Evidence & Data

ItemData pointSource quality
Corpus35M peer-reviewed publications, mandatory citations, refuses inconclusive queriesG2 — independent research
Adoption claim"Most popular AI for doctors in the United States"G1 — company-adjacent press release, treat as asserted
Valuation narrative"$500M company for $15B"G3 — paid journalism, people-familiar sourcing
Management posture"Runs the company more like a hedge fund"G3 — anonymous characterization
Reported round$250M (reported), leading the tape two days runningQL briefings, 9/27–9/28

On the required directional inputs, we are explicit about absence: there is no sell-side coverage, so no majority recommendation or price-target forecast exists — we state that rather than fabricate a proxy. There is no listed price, so no technical indicator stack applies; the nearest technical read is the funding tape itself, where a round leading the tape on consecutive days signals a still-open financing window for AI healthcare. News sentiment is constructive but thin: the Every Cure partnership is brand-affirming but revenue-light, and Nadler's "learn the hard way" comments at Semafor read as reputation management against cognitive-offloading criticism. Macro: the 2026 private AI financing cycle remains accommodative — a $250M reported round leading the tape confirms it — which means the mark is a choice, not a constraint, and the signal content of the next round is high.

The consensus view is that OpenEvidence is the category winner and the $15B number is merely early. The variant perception this note sells: adoption is real (the G1 adoption claim is at least directionally credible given the citation-first design), but adoption is not economics — no disclosed revenue, no disclosed pricing, no disclosed retention supports a 30x step-up from $500M to $15B, and the G3 reporting suggests the step-up is financial engineering narrative, not a DCF. The market is mispricing the difference between winning the category and being able to charge for it.

Scenario Analysis

ScenarioProbabilityPrice pathThesis impact
Bull30%Next round marks ≥ $15B; pharma monetization disclosedConfirms scarcity premium; upgrade case builds
Base45%Round marks $10–14B; scale-first, revenue still undisclosedWatch maintained; ask partially walked
Bear25%Round stalls or marks <$8B; incumbent (Epic/Alphabet) bundles a free rivalAdoption moat erodes; bear case live
Scenario probabilities — engine-assigned odds, price paths on hover
Bull30%Base45%Bear25%

EV = 0.30×$18B + 0.45×$12B + 0.25×$7B = $12.55B, ≈ -16% vs. the ~$15B reported ask — the weighted fair value sits below the narrative price, which is precisely why this is a WATCH and not a BULLISH.

Catalysts & Risks

Catalysts: a priced round printing at or above $15B with named revenue traction; disclosure of pharmaceutical advertising or enterprise contracts; expansion beyond the Every Cure-style nonprofit partnerships into paid distribution. Risks: monetization remains unproven into 2027 while the valuation markup compounds (G3 challenges the clean bull case); incumbents bundling clinical AI at zero price; regulatory tightening on physician AI reliance, a risk management itself flags via the Semafor cognitive-offloading commentary; and single-founder key-person concentration implied by the hedge-fund-style management characterization.

What Changes Our Mind

The trigger table is falsifiable and dated against the next priced event:

TriggerLevelAction
Next round mark≥ $15B with disclosed revenue tractionUpgrade to BULLISH
Next round mark$10–14BStay WATCH; ask walked, thesis intact
Next round mark or sale< $10BInvalidates the scarcity-premium thesis; BEARISH framing

Our invalidating claim is strict: a next priced mark below $10B breaks the adoption-to-monetization handoff this entire markup anticipates. Secondary falsifiers: a credible free clinical assistant bundled by Epic or Alphabet into >50% of US hospital EHRs, or a disclosed-material hallucination liability event — either converts this WATCH to BEARISH on the next coverage pass. Educational market commentary, not investment advice.

What Changes Our Mind

Our WATCH stance on OpenEvidence is contingent on the bridge between high-frequency clinical adoption and tangible enterprise monetization. We will move to a BULLISH stance if the next priced round captures a valuation of $15 billion or greater while simultaneously providing verifiable disclosure of recurring revenue or high-value pharmaceutical enterprise contracts. Such data would confirm that the platform has successfully converted physician engagement into a defensible, high-margin economic moat.

Conversely, our conviction shifts to BEARISH if the next capital raise reflects a significant down-round or a "flat" valuation below $8 billion, as this would signal a collapse in investor confidence regarding the firm's ability to monetize its massive citation corpus. Furthermore, if major incumbents like Epic Systems or Alphabet announce integrated, free-to-access clinical AI toolsets that directly cannibalize OpenEvidence’s core utility, the thesis of an independent, standalone valuation of $15B becomes untenable. Finally, any regulatory findings that categorize the platform’s "cognitive-offloading" as a clinical liability would force a fundamental reassessment of the company’s long-term market viability and strategic independence.

Related QuantLogix coverage

More from QL Research

Share this research

Browse the full graded library →

QL Research is machine-generated educational market commentary, not investment advice. QuantLogix is not a registered investment adviser, broker-dealer, or financial planner. Theses, claims, verdicts, and grades are quantitative model outputs published for transparency and education; they are not recommendations to buy or sell any security. Markets involve substantial risk of loss. Past graded performance does not guarantee future results.